These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12670745)

  • 1. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.
    Jeng JR
    Am J Hypertens; 2003 Apr; 16(4):290-6. PubMed ID: 12670745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women.
    Kim KN; Kim KM; Kim BT; Joo NS; Cho DY; Lee DJ
    Chin Med J (Engl); 2012 Apr; 125(7):1249-53. PubMed ID: 22613596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The influences of genetic and environmental factors on plasma plasminogen activator inhibitor-1 levels in patients with essential hypertension].
    Song Y; Xu W; Chen Y; Che L; Wang Q; Zhou X; Wu J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Dec; 16(6):374-6. PubMed ID: 10581347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
    Diamanti-Kandarakis E; Palioniko G; Alexandraki K; Bergiele A; Koutsouba T; Bartzis M
    Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of interleukin-6 gene G-174C polymorphism and plasma plasminogen activator inhibitor-1 level in Chinese patients with and without hypertension.
    Jeng JR; Wang JH; Liu WS; Chen SP; Chen MY; Wu MH; Hsu WL; Lin SZ
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):517-22. PubMed ID: 15831362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes.
    Margaglione M; Grandone E; Vecchione G; Cappucci G; Giuliani N; Colaizzo D; Celentano E; Panico S; Di Minno G
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2082-7. PubMed ID: 9351375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.
    Lin S; Huiya Z; Bo L; Wei W; Yongmei G
    Endocrine; 2009 Dec; 36(3):503-9. PubMed ID: 19856137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
    Zietz B; Buechler C; Drobnik W; Herfarth H; Schölmerich J; Schäffler A
    Endocr Res; 2004 Aug; 30(3):443-53. PubMed ID: 15554360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
    Seguí R; Estellés A; Mira Y; España F; Villa P; Falcó C; Vayá A; Grancha S; Ferrando F; Aznar J
    Br J Haematol; 2000 Oct; 111(1):122-8. PubMed ID: 11091191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China.
    Zhan M; Zhou Y; Han Z
    Chin Med J (Engl); 2003 Nov; 116(11):1707-10. PubMed ID: 14642142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
    Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
    Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke.
    Chen CH; Eng HL; Chang CJ; Tsai TT; Lai ML; Chen HY; Liu CJ; Lin TM
    J Lab Clin Med; 2003 Aug; 142(2):100-5. PubMed ID: 12960956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
    Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
    Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
    Burzotta F; Iacoviello L; Di Castelnuovo A; Zamparelli R; D'Orazio A; Amore C; Schiavello R; Donati MB; Maseri A; Possati G; Andreotti F
    J Thromb Thrombolysis; 2003 Dec; 16(3):149-54. PubMed ID: 15087600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.
    Ossei-Gerning N; Mansfield MW; Stickland MH; Wilson IJ; Grant PJ
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):33-7. PubMed ID: 9012634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.